HilleVax, Inc., (HLVX): Price and Financial Metrics


HilleVax, Inc., (HLVX): $15.06

-0.72 (-4.56%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add HLVX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

HLVX Stock Price Chart Interactive Chart >

Price chart for HLVX

HLVX Price/Volume Stats

Current price $15.06 52-week high $24.42
Prev. close $15.78 52-week low $7.90
Day low $15.05 Volume 28,300
Day high $16.10 Avg. volume 34,311
50-day MA $16.43 Dividend yield N/A
200-day MA $0.00 Market Cap 502.18M

HilleVax, Inc., (HLVX) Company Bio


HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.


HLVX Latest News Stream


Event/Time News Detail
Loading, please wait...

HLVX Latest Social Stream


Loading social stream, please wait...

View Full HLVX Social Stream

Latest HLVX News From Around the Web

Below are the latest news stories about HILLEVAX INC that investors may wish to consider to help them evaluate HLVX as an investment opportunity.

HilleVax Announces Executive Management Appointments and Promotions

BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appointment of Ozzie Berger as Senior Vice President of Regulatory Affairs, the promotion of Anju Chatterji to Chief Technical Officer, and the promotion of Shane Maltbie to Chief Financial Officer. As part of a planned transition in connection with Mr. Maltbie’s promotion, David Socks will focus on busin

Yahoo | January 9, 2023

HilleVax to Present at the 41st Annual J.P. Morgan Healthcare Conference

BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California on Monday, January 9, 2023, at 4:30 p.m. EST / 1:30 p.m. PST. HIL-214, HilleVax’s investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gast

Yahoo | January 4, 2023

HilleVax, Boston’s biggest IPO of 2022, wants to end common norovirus effect

Just nine IPOs were recorded among Boston-area companies in 2022, after more than two dozen went public in 2021. In fact, 10 IPOs last year raised more money than this year's largest, HilleVax. Here's the infection Hillevax hopes to tackle.

Yahoo | December 30, 2022

After Plunging 32.4% in 4 Weeks, Here's Why the Trend Might Reverse for HilleVax, Inc. (HLVX)

HilleVax, Inc. (HLVX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Yahoo | December 14, 2022

Down 25.2% in 4 Weeks, Here's Why You Should You Buy the Dip in HilleVax, Inc. (HLVX)

HilleVax, Inc. (HLVX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Yahoo | December 13, 2022

Read More 'HLVX' Stories Here

HLVX Price Returns

1-mo -9.98%
3-mo -29.56%
6-mo 28.39%
1-year N/A
3-year N/A
5-year N/A
YTD -9.98%
2022 N/A
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6933 seconds.